Altimmune (NASDAQ:ALT) Stock Price Down 5.1% - Time to Sell?

Altimmune, Inc. (NASDAQ:ALT - Get Free Report)'s share price was down 5.1% on Tuesday . The stock traded as low as $8.52 and last traded at $8.54. Approximately 316,980 shares were traded during trading, a decline of 92% from the average daily volume of 3,820,236 shares. The stock had previously closed at $9.00.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ALT shares. UBS Group began coverage on Altimmune in a report on Tuesday, November 12th. They set a "buy" rating and a $26.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $20.00.

Altimmune Price Performance

The stock has a market capitalization of $597.45 million, a PE ratio of -5.42 and a beta of 0.15. The business's fifty day moving average price is $7.81 and its two-hundred day moving average price is $7.08.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million during the quarter. During the same period last year, the business earned ($0.39) EPS. As a group, equities research analysts anticipate that Altimmune, Inc. will post -1.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Altimmune

A number of institutional investors and hedge funds have recently bought and sold shares of the business. B. Riley Wealth Advisors Inc. grew its stake in shares of Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company's stock worth $144,000 after acquiring an additional 2,687 shares in the last quarter. Creative Planning lifted its holdings in shares of Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company's stock valued at $113,000 after purchasing an additional 3,132 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Altimmune by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company's stock valued at $1,299,000 after purchasing an additional 4,772 shares during the period. Larson Financial Group LLC purchased a new position in shares of Altimmune during the third quarter worth approximately $31,000. Finally, Arizona State Retirement System grew its position in Altimmune by 34.4% during the 2nd quarter. Arizona State Retirement System now owns 19,847 shares of the company's stock worth $132,000 after purchasing an additional 5,081 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.